Use of composite scores in the quantification of deterioration in multiple sclerosis

Abstract

Keywords

Get full access to this article

View all access options for this article.

References

Kurtzke JF. (1983) Rating neurological impairment in multiple sclerosis: An expanded disability status scale (EDSS) . Neurology 33: 1444-1452 .

Weinshenker BG. (1996) Clinical outcome measures for multiple sclerosis. In: Goodkin DE , Rudick RA , eds. Multiple sclerosis: advances in clinical trial design, treatment, and future perspectives. Springer: London , pp 105-122.

Petkau AJ. (1996) Statistical and design considerations for multiple sclerosis clinical trials. In: Goodkin DE , Rudick RA , eds. Multiple sclerosis: advances in clinical trial design, treatment and future perspectives. Springer: London , pp 63-103.

Whitaker JN , McFarland HF , Rudge P , Reingold SC. (1995) Outcomes assessment in multiple sclerosis clinical trials: a critical analysis . Multiple Sclerosis 1: 37-47 .

Sharrack B , Hughes RAC. (1996) Clinical scales for multiple sclerosis . J Neurol Sci 135: 1-9 .

Goodkin DE et al. (1996) Low-Dose (7.5 mg) oral Methotrexate reduces the rate of progression in chronic progressive Multiple Sclerosis . Ann Neurol 37: 30-40 .

Rudick R et al. (1996) Clinical outcomes assessment in multiple sclerosis . Ann Neurol 40: 469-479 .

Rudick R et al. (1997) Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force . Ann Neurol 42: 379-382 .